We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+15.31%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$51.8M
AUM Growth
+$4.44M
Cap. Flow
-$659K
Cap. Flow %
-1.27%
Top 10 Hldgs %
97.02%
Holding
55
New
45
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$5.02M
2
GSK icon
GSK
GSK
+$5M
3
CAH icon
Cardinal Health
CAH
+$2.28M
4
UTMD icon
Utah Medical Products
UTMD
+$730K
5
UNH icon
UnitedHealth
UNH
+$201K

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$4.42M
2
GILD icon
Gilead Sciences
GILD
+$3.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$2.49M
4
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$2.26M
5
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.13M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
51
DELISTED
Merus
MRUS
$4.42K 0.01%
+286
New +$5.04K
ACLX
52
DELISTED
Arcellx
ACLX
$4.4K 0.01%
+142
New +$3.26K
DNLI icon
53
Denali Therapeutics
DNLI
$4.04B
$4.39K 0.01%
+158
New +$4.7K
MCK icon
54
McKesson
MCK
$104B
– –
-13,000
Closed -$4.42M
OPNT
55
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
– –
-210,000
Closed -$2.26M
1 2
3

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
OCMH
Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

HealthInvest Partners's Q4 2022 Portfolio in Review

As of Q4 2022, HealthInvest Partners held 55 positions worth $51.8M, up 9.4% from $47.3M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

HealthInvest Partners's Q4 2022 filing shows 45 new, 2 increased, 5 reduced and 2 closed positions. Its largest new stake was CVS Health: 52,000 shares worth $4.85M. The largest sale was McKesson, an estimated $4.42M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • HealthInvest Partners's largest Q4 2022 buy was CVS Health: 52,000 shares worth $4.85M.
  • HealthInvest Partners added most to Cardinal Health in Q4 2022, an estimated $2.28M increase.
  • HealthInvest Partners's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $3.5M.
  • HealthInvest Partners fully exited McKesson in Q4 2022, selling an estimated $4.42M.
  • HealthInvest Partners's ten largest holdings make up 97% of its $51.8M portfolio in Q4 2022.
  • HealthInvest Partners opened 45 new positions and closed 2 in Q4 2022.
  • HealthInvest Partners's portfolio value rose 9.4% quarter-over-quarter to $51.8M.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.